Willowcroft Pharm, Inc., a company based in Colorado, has announced that they have a promising treatment for laminitis in an injectable drug they've developed called Laminil. If the drug receives FDA approval for use in laminitic horses, it could be the first and currently only commercially available treatment for the disease.
Keeping horse's legs healthy
Laminil is the only injectable drug designed to halt the laminitis cascade and the inflammatory response in horses that is currently going through the FDA regulatory process.
It is the only injectable drug designed to halt the laminitis cascade and the inflammatory response that is going through the FDA regulatory process at this time.
According to company information, Laminil is an injectable drug developed to halt the inflammatory response and laminitis cascade of acute laminitis and active chronic laminitis.
Laminil is designed to inhibit inflammatory mediators and other chemicals from being released from the mast cell in excess. When the inflammatory mediators are not released in excess, then the laminitis cascade is broken/halted. This allows the horse to start healing, though healing may take time.
More than 40 horses with an acute or active chronic case of laminitis received treatment with Laminil this spring.
The reaction from owners and veterinarians of those horses was very positive across the board in describing how the horses responded.
Many veterinarians stated they wanted to continue receiving shipments of the drug to treat future cases, including vets at two world-respected equine hospitals.
Data collection has now been completed, and Willowcroft Pharm, Inc. is restricted by the FDA in what they can do with this investigational drug as they wait for approval from the FDA.
Horse owners who are interested in this new drug are encouraged to register to receive updates on Laminil. According to the company, you can rest assured that they will keep your name and email address private. Not only will you receive the latest news, but they will have a gauge of interest in Laminil and can share that interest level with the FDA and equine veterinarians.
Willowcroft Pharm Inc.
P.O. Box 620694
Littleton, Colorado 80162
Phone: (303) 875-7402
Email: charlie@solucian.com